JPWO2020150290A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020150290A5 JPWO2020150290A5 JP2021540587A JP2021540587A JPWO2020150290A5 JP WO2020150290 A5 JPWO2020150290 A5 JP WO2020150290A5 JP 2021540587 A JP2021540587 A JP 2021540587A JP 2021540587 A JP2021540587 A JP 2021540587A JP WO2020150290 A5 JPWO2020150290 A5 JP WO2020150290A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- stmn2
- disease
- composition
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962792276P | 2019-01-14 | 2019-01-14 | |
| US62/792,276 | 2019-01-14 | ||
| PCT/US2020/013581 WO2020150290A2 (en) | 2019-01-14 | 2020-01-14 | Methods and compositions for restoring stmn2 levels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517117A JP2022517117A (ja) | 2022-03-04 |
| JP2022517117A5 JP2022517117A5 (https=) | 2023-01-25 |
| JPWO2020150290A5 true JPWO2020150290A5 (https=) | 2023-01-25 |
Family
ID=71613551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540587A Pending JP2022517117A (ja) | 2019-01-14 | 2020-01-14 | Ｓｔｍｎ２レベルを回復させるための方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12496327B2 (https=) |
| EP (1) | EP3911411A4 (https=) |
| JP (1) | JP2022517117A (https=) |
| CN (1) | CN114173821A (https=) |
| CA (1) | CA3126918A1 (https=) |
| WO (1) | WO2020150290A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3103429A1 (en) | 2018-06-14 | 2019-12-19 | Don W. Cleveland | Compounds and methods for increasing stmn2 expression |
| EP4162051A4 (en) * | 2020-06-03 | 2025-07-09 | Quralis Corp | TREATMENT OF NEUROLOGICAL DISEASES USING GENE TRANSCRIPT MODULATORS |
| WO2022018155A1 (en) * | 2020-07-23 | 2022-01-27 | F. Hoffmann-La Roche Ag | Lna oligonucleotides for splice modulation of stmn2 |
| US20250270548A1 (en) * | 2020-12-07 | 2025-08-28 | Perron Institute for Neurological and Translational Science Limited | Compositions and methods for treating tardbp associated diseases |
| CA3215808A1 (en) * | 2021-04-22 | 2022-10-27 | Roger Chung | Modified polypeptides and uses thereof |
| KR20240052763A (ko) * | 2021-08-11 | 2024-04-23 | 아버 바이오테크놀로지스, 인크. | 스타스민 2 (stmn2)를 표적화하는 rna 가이드를 포함하는 유전자 편집 시스템 및 이의 용도 |
| AU2022402929A1 (en) * | 2021-12-03 | 2024-06-13 | Quralis Corporation | Splice switcher antisense oligonucleotides with modified backbone chemistries |
| EP4724426A1 (en) * | 2023-06-12 | 2026-04-15 | The General Hospital Corporation | Statin derivatives and methods of using the same |
| WO2025076126A1 (en) * | 2023-10-02 | 2025-04-10 | Emory University | Agents that bind nucleic acids encoding elavl3 cryptic exons, pharmaceutical compositions, and uses in managing neurological diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1815863A1 (en) * | 2006-02-03 | 2007-08-08 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Use of TLR3 agonists for the treatment of neurodegenerative disorders |
| CA2653974A1 (en) | 2006-05-30 | 2008-02-14 | Mayo Foundation For Medical Education And Research | Detecting and treating dementia |
| WO2013169793A2 (en) * | 2012-05-09 | 2013-11-14 | Ipierian, Inc. | Methods and compositions for tdp-43 proteinopathies |
| US9612534B2 (en) * | 2015-03-31 | 2017-04-04 | Tokyo Electron Limited | Exposure dose homogenization through rotation, translation, and variable processing conditions |
| GB201703123D0 (en) * | 2017-02-27 | 2017-04-12 | St George's Hospital Medical School | Biomarkers |
| CA3103429A1 (en) | 2018-06-14 | 2019-12-19 | Don W. Cleveland | Compounds and methods for increasing stmn2 expression |
| JP7795914B2 (ja) | 2019-06-03 | 2026-01-08 | クラリス コーポレーション | 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法 |
| EP4127172A4 (en) | 2020-03-25 | 2025-06-04 | President and Fellows of Harvard College | Methods and compositions for restoring STMN2 levels |
-
2020
- 2020-01-14 WO PCT/US2020/013581 patent/WO2020150290A2/en not_active Ceased
- 2020-01-14 US US17/423,104 patent/US12496327B2/en active Active
- 2020-01-14 EP EP20740861.8A patent/EP3911411A4/en active Pending
- 2020-01-14 CN CN202080020187.5A patent/CN114173821A/zh active Pending
- 2020-01-14 CA CA3126918A patent/CA3126918A1/en active Pending
- 2020-01-14 JP JP2021540587A patent/JP2022517117A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | FBW7 mediates senescence and pulmonary fibrosis through telomere uncapping | |
| Ermak et al. | Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer's disease | |
| Hasan et al. | Transcriptomic analysis of frontotemporal lobar degeneration with TDP-43 pathology reveals cellular alterations across multiple brain regions | |
| Cui et al. | Cytoplasmic polyadenylation is a major mRNA regulator during oogenesis and egg activation in Drosophila | |
| US9486521B2 (en) | Therapeutic applications targeting SARM1 | |
| Mercer et al. | Hspb7 is a cardioprotective chaperone facilitating sarcomeric proteostasis | |
| Sousounis et al. | Eya2 promotes cell cycle progression by regulating DNA damage response during vertebrate limb regeneration | |
| De Castro et al. | Lamin b1 polymorphism influences morphology of the nuclear envelope, cell cycle progression, and risk of neural tube defects in mice | |
| Stoner et al. | Neuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein | |
| JPWO2020150290A5 (https=) | ||
| JP2008512984A5 (https=) | ||
| US20070199080A1 (en) | Diagnostic and therapeutic use of F-box proteins for Alzheimer's disease and related neurodegenerative disorders | |
| Somavarapu et al. | Direct correlation of cell toxicity to conformational ensembles of genetic Aβ Variants | |
| Ganesan et al. | Identification and expression analysis of the zebrafish orthologues of the mammalian MAP1LC3 gene family | |
| Almaguer-Mederos et al. | Multiomics approach identifies SERPINB1 as candidate biomarker for spinocerebellar ataxia type 2 | |
| Yulyaningsih et al. | DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the effects of neurodegeneration caused by the Integrated Stress Response | |
| AU2003228591A1 (en) | Compositions and methods relating to endothelial cell signaling using the protease activated receptor (par1) | |
| Lim et al. | Analysis of nicastrin gene phylogeny and expression in zebrafish | |
| JP2021099351A (ja) | 生体サンプル中のミトコンドリア複製の機能不全をインビトロで調査するための方法、そのキット及び使用、早老症様の症候群又は症状に対する治療方法、並びに特定のプロテアーゼ阻害剤及び／又はニトロソ酸化還元ストレススカベンジャー化合物を同定するためのスクリーニング方法 | |
| Nandi et al. | A phosphoswitch at acinus-serine437 controls autophagic responses to cadmium exposure and neurodegenerative stress | |
| US20120252737A1 (en) | Methods for Diagnosing and Treating Cancer | |
| Connie et al. | Brain tau isoform mRNA and protein correlation in PSP brain | |
| KR20150094311A (ko) | 퇴행성 신경계 질환 치료제 스크리닝 방법 | |
| Nalbandian et al. | Global gene expression profiling in R155H Knock‐In murine model of VCP disease | |
| US20100297623A1 (en) | NOVEL HUMAN ssDNA BINDING PROTEINS AND METHODS OF CANCER DIAGNOSIS |